argenx SE (ARGX)
NASDAQ: ARGX · Real-Time Price · USD
586.70
-8.88 (-1.49%)
Nov 4, 2024, 1:05 PM EST - Market open
argenx SE Revenue
argenx SE had revenue of $588.88M in the quarter ending September 30, 2024, with 73.28% growth. This brings the company's revenue in the last twelve months to $1.91B, up 85.56% year-over-year. In the year 2023, argenx SE had annual revenue of $1.27B with 187.66% growth.
Revenue (ttm)
$1.91B
Revenue Growth
+85.56%
P/S Ratio
n/a
Revenue / Employee
$1,662,595
Employees
1,148
Market Cap
35.78B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.27B | 827.59M | 187.66% |
Dec 31, 2022 | 441.01M | -87.26M | -16.52% |
Dec 31, 2021 | 528.27M | 466.31M | 752.59% |
Dec 31, 2020 | 61.96M | -30.85M | -33.24% |
Dec 31, 2019 | 92.81M | 63.58M | 217.51% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Centene | 146.20B |
Humana | 115.01B |
GE HealthCare Technologies | 19.56B |
IQVIA Holdings | 15.32B |
Agilent Technologies | 6.50B |
Edwards Lifesciences | 6.31B |
ResMed | 4.81B |
IDEXX Laboratories | 3.84B |
ARGX News
- 3 days ago - Argenx: Strong CIDP Launch, But gMG Growth Propels Q3 Sales Beat - Seeking Alpha
- 4 days ago - argenx SE (ARGX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 4 days ago - argenx Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 11 days ago - argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024 - GlobeNewsWire
- 20 days ago - argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions - GlobeNewsWire
- 5 weeks ago - argenx: Myositis Data Could Add Billions In Value - Seeking Alpha
- 6 weeks ago - argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy - GlobeNewsWire
- 2 months ago - argenx to Present at Upcoming Investor Conferences - GlobeNewsWire